Connor, Clark & Lunn Investment Management Ltd.

Position in CRL — Charles River Laboratories International, Inc.

CIK 1596800 VANCOUVER, A1

Position in CRL

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$9,413,325

-$17,348,113 QoQ

Shares Held

54,570

-59.3% QoQ

Ownership

0.113%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

12 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $206,312,128 across 18 Diagnostics & Research names. CRL ranks #5 (4.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	MEDP	Medpace Holdings, Inc.	134,838	$64,747,859
2	ILMN	Illumina, Inc.	202,742	$24,989,978
3	DHR	Danaher Corp /De/	129,426	$24,539,169
4	GH	Guardant Health, Inc.	254,788	$23,534,767
5	CRL	Charles River Laboratories International, Inc. This page	54,570	$9,413,325
6	CSTL	Castle Biosciences Inc	377,082	$9,257,363
7	ADPT	Adaptive Biotechnologies Corp	649,627	$9,016,822
8	NEO	Neogenomics Inc	938,052	$6,960,345

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$9,413,325	54,570	-59.3%	Shares	Sole	2026-05-11
2025-12-31	$26,761,438	134,156	-25.7%	Shares	Sole	2026-02-10
2025-09-30	$28,251,043	180,564	-5.6%	Shares	Sole	2025-11-13
2025-06-30	$29,021,093	191,268	+670.0%	Shares	Sole	2025-08-07
2025-03-31	$3,738,766	24,839	+45.9%	Shares	Sole	2025-05-12
2023-12-31	$4,025,182	17,027	+0.6%	Shares	Sole	2024-02-09
2022-06-30	$3,621,014	16,923	-35.0%	Shares	Sole	2022-08-05
2022-03-31	$7,392,591	26,033	-42.2%	Shares	Sole	2022-05-12
2021-12-31	$16,962,258	45,019	+74.6%	Shares	Sole	2022-02-10
2021-09-30	$10,641,108	25,786	+251.3%	Shares	Sole	2021-11-12
2021-06-30	$2,715,212	7,340	-12.6%	Shares	Sole	2021-08-12
2020-03-31	$1,059,659	8,396	—	Shares	Sole	2020-05-13
No filing history on record for this holder in this stock.